Nephrogenic systemic fibrosis versus contrast‐induced nephropathy: Risks and benefits of contrast‐enhanced MR and CT in renally impaired patients |
| |
| Authors: | Diego R. Martin MD PhD Richard C. Semelka MD Arlene Chapman MD Harm Peters MD Paul J. Finn MD PhD Bobby Kalb MD Henrik Thomsen MD |
| |
| Affiliation: | 1. Department of Radiology, Emory University School of Medicine, Atlanta, Georgia, USA;2. Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, USA;3. Department of Medicine, Division of Nephrology, Emory University School of Medicine, Atlanta, Georgia, USA;4. Department of Nephrology, Humboldt University, Berlin, Germany;5. Department of Radiology, UCLA Medical Center, Los Angeles, California, USA;6. Diagnostic Radiology, Copenhagen University Hospital, Herlev, Denmark;7. Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark |
| |
| Abstract: | Magnetic resonance imaging (MRI) and computed tomography (CT) have become essential to diagnostic evaluation of many, or most, important medically and surgically treated diseases. It is important to consider comprehensively the implications in making decisions when choosing one or the other cross‐sectional imaging modality. Factors to consider include the relative risks of the contrast agent. Other factors include the relative procedural risks, including radiation risks and the relative expected diagnostic yield of the examination technique ( 1 , 2 ). In this review we describe both nephrogenic systemic fibrosis and contrast‐induced nephropathy to compare the implications with regard to relative risks and benefits of contrast‐enhanced MRI or CT in patients with impaired renal function. J. Magn. Reson. Imaging 2009;30:1350–1356. © 2009 Wiley‐Liss, Inc. |
| |
| Keywords: | nephrogenic systemic fibrosis contrast induced nephropathy contrast reactions gadolinium iodinated contrast contrast agents |
|
|
